Table 4.
Factors affecting overall survival
| Group | Subgroup | n | Median OS (months) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| HR (95%CI) | P | HR (95%CI) | P | ||||
| Age (years) | ≤60 | 266 | 13.2 | 1.0 | 0.037 | 1.1 (0.8-1.5) | 0.416 |
| >60 | 270 | 10.0 | 1.3 (1.0-1.6) | ||||
| Sex | Male | 419 | 10.5 | 1.0 | 0.049 | 1.1 (0.7-1.6) | 0.786 |
| Female | 117 | 16.3 | 0.7 (0.5-1.0) | ||||
| Education | Up to primary level | 217 | 9.1 | 1.0 | 0.032 | 0.9 (0.6-1.2) | 0.466 |
| Above primary level | 224 | 13.2 | 0.7 (0.6-0.9) | ||||
| NSCLC pathology | SCC | 153 | 9.9 | 1.0 | 0.9 (0.8-1.2) | 0.910 | |
| ADC | 275 | 14.5 | 0.6 (0.5-0.9) | 0.004 | |||
| NSCLC (NOS) | 108 | 9.3 | 1.1 (0.8-1.6) | 0.477 | |||
| ECOG | 0,1 | 253 | 16.9 | 1.0 | <0.001 | 2.4 (1.8-3.3) | <0.001 |
| 2,3,4 | 200 | 7.9 | 2.2 (1.7-2.9) | ||||
| Smoking | Never smoker | 173 | 17.1 | 1.0 | <0.001 | 1.6 (1.2-2.3) | 0.004 |
| Chronic smoker | 342 | 9.6 | 1.8 (1.4-2.4) | ||||
| Treatment | Chemotherapy | 464 | 10.5 | 1.0 | |||
| EGFR inhibitors | 40 | NR | 0.3 (0.2-0.6) | <0.001 | 0.4 (0.2-0.9) | 0.017 | |
| ALK inhibitors | 9 | NR | 0.1 (0.0-0.9) | 0.048 | 0.2 (0.1-1.8) | 0.172 | |
| Compassionate based treatment | 23 | 4.7 | 1.8 (1.1-3.2) | 0.030 | 2.0 (1.0-4.2) | 0.054 | |
OS: Overall survival, NSCLC: Non-small cell lung cancer, NOS: Not otherwise specified, ECOG: Eastern cooperative oncology group, EGFR: Epidermal growth factor receptor, ALK: Anaplastic lymphoma receptor tyrosine kinase, TKI’s: Tyrosine kinase inhibitors, HR: Hazard ratio, CI: Confidence interval, SCC: Squamous cell carcinoma, ADC: Adenocarcinoma, NR: Not reached